EFFICACY AND SAFETY

ATLAS-2M study design

ATLAS-2M Phase 3b, randomised, multicentre, parallel-arm, open-label, non-inferiority study1

ATLAS-2M was designed to demonstrate that Every 2-Month VOCABRIA + REKAMBYS was non-inferior to Monthly VOCABRIA + REKAMBYS.1 ATLAS-2M included 1045 virologically suppressed patients living with HIV-1, with some participants transitioning from the ATLAS clinical trial.1,2

ATLAS-2M trial design visual

*Both tablets are to be taken together with a meal at the same time each day, for at least 28 days.1,3

63% icon

of patients previously received daily oral ARV therapy1,2

37% icon

of patients previously received Monthly VOCABRIA + REKAMBYS1,2

ATLAS-2M included a range of patients2

  • Baseline Patient Characteristics

    Baseline Patient characteristics for ATLAS 1 and 2M trials

    *Adult patients with HIV-1 were virologically suppressed for ≥6 months.2 Most patients’ prior regimen was a daily oral ARV therapy that included 2 NRTIs + third agent (INI, NNRTI, or PI); however, the prior therapy for some patients was Q1M VOCABRIA + REKAMBYS from ATLAS.2

Colleague Testimonials

Hear what colleagues say about their experiences with long-acting therapy

ARV=antiretroviral; HIV-1=human immunodeficiency virus type 1; INI=integrase inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor; PI=protease inhibitor; Q1M=monthly; Q2M=once every 2 months.

References:

  1. VOCABRIA Summary of Product Characteristics. ViiV Healthcare.
  2. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. Published online ahead of print: December 9, 2020. doi: 10.1016/S0140-6736(20)32666-0.
  3. REKAMBYS Summary of Product Characteristics. Janssen Healthcare.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

REKAMBYS (rilpivirine long acting injection), including the trademark is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.

PM-GB-CBR-WCNT-210001v3 I April 2022

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.